Genmab Reports Strong DARZALEX® Q3 Sales
Ticker: GNMSF · Form: 6-K · Filed: Oct 17, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: sales-update, pharmaceuticals, drug-performance
Related Tickers: GMAB
TL;DR
Genmab's DARZALEX® crushed Q3 sales expectations!
AI Summary
Genmab A/S announced on October 14, 2025, that net sales of its drug DARZALEX® (daratumumab) for the third quarter of 2025 exceeded expectations. The company is a Danish biotechnology firm focused on developing and manufacturing antibody therapeutics.
Why It Matters
This filing indicates strong commercial performance for a key Genmab product, potentially impacting future revenue and investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine report of sales figures and does not contain significant new risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- DARZALEX® (product) — Drug name
- daratumumab (drug_name) — Active ingredient of DARZALEX®
- October 14, 2025 (date) — Date of company announcement
- Third Quarter 2025 (period) — Reporting period for sales
FAQ
What specific net sales figures were announced for DARZALEX® in the third quarter of 2025?
The filing states that Genmab announced net sales of DARZALEX® for the third quarter of 2025, but the specific dollar amount is not detailed within this Form 6-K document itself, referring to a separate company announcement.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer providing a company announcement dated October 14, 2025, regarding Genmab's net sales of DARZALEX® for the third quarter.
What is DARZALEX®?
DARZALEX® is a drug developed by Genmab, with the active ingredient daratumumab, and its net sales for the third quarter of 2025 are the subject of this announcement.
When was the company announcement regarding DARZALEX® sales made?
The company announcement was dated October 14, 2025.
Does this filing include Genmab's annual report?
No, this is a Form 6-K, which is a report of a foreign private issuer, and it indicates that Genmab files annual reports under Form 20-F, not this form.
Filing Stats: 226 words · 1 min read · ~1 pages · Grade level 15.1 · Accepted 2025-10-16 19:30:43
Filing Documents
- gmab_20251014xx6k.htm (6-K) — 14KB
- gmab_20251014xxex99d1.htm (EX-99.1) — 15KB
- genmab_logo.jpg (GRAPHIC) — 56KB
- 0001434265-25-000087.txt ( ) — 104KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated October 14, 2025 Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE OCTOBER 14, 2025